ReviewBMC cardiovascular disorders2025
Multidisciplinary treatment for primary cardiac angiosarcoma: a case report and overview of the literature.
Review in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Editorial: introducing special collection on cancer and cardiovascular disorders.BMC cardiovascular disorders · 2026Article
- Primary Cardiac Angiosarcoma in a Young Male: Rare Presentation With Right Atrial Endocardial Dissection and Right Coronary Artery Tumor Fistula.Clinical case reports · 2026Article
- Case Report: Intracardiac echocardiography-guided pulmonary vein stenting for pulmonary vein stenosis caused by a left atrial tumor.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrimary cardiac angiosarcoma is rare and highly invasive to myocardial tissue and prone to metastasis. Surgery is an effective treatment, but it is difficult and risky. Postoperative therapy could improve survival rate, but specific regimens are controversial. CASE PRESENTATION: We herein demonstrated the management experience of a patient with primary cardiac angiosarcoma at 19 weeks of pregnancy, which can be used as a reference for other patients. She underwent surgical R1 resection during pregnancy, but the fetus aborted spontaneously 4 h after surgery. Under the care of our multidisciplinary team, she also received radiotherapy, chemotherapy, and targeted therapy. After that, she was evaluated as stable disease at 14th months after surgery. She developed multiple bone metastases 16th months after surgery and finally died in the 18th month after surgery.
conclusionSurgical resection of cardiac angiosarcoma should remove as much tumor tissue as possible. Chemotherapy and targeted therapy are beneficial in shrinking tumors and control disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.